Problematically, the only currently available hypnozoitocidal therapy, the 8-aminoquinoline primaquine regimen, is typically 14-days in duration and exposes glucose-6-phosphate dehydrogenase (G6PD) deficient patients–a widespread genetic disorder impacting 8% of residents of malaria endemic nations [20]–to potentially life-threatening acute haemolytic anaemia. Here, G6PD is linked to non-autoimmune hemolytic anemia.